Funding Support From NMRC Clinical Trial Grant

CytoMed Therapeutics

07/10/2024 12:05

Oct 7 (Reuters) - CytoMed Therapeutics Ltd  F98.F :
    * CYTOMED THERAPEUTICS’ FIRST-IN-HUMAN PHASE I ANGELICA
CLINICAL
TRIAL USING ITS PATENTED DONOR ALLOGENEIC CHIMERIC ANTIGEN
RECEPTOR T CELL (CAR-T CELL) AGAINST BLOOD AND SOLID TUMORS
RECEIVED CO-FUNDING SUPPORT FROM THE NMRC CLINICAL TRIAL GRANT

Source text for Eikon:  ID:nGNX8hX6fs 
Further company coverage:  F98.F 

 ((Reuters.Briefs@thomsonreuters.com;))